National Institute of Allergy and Infectious Diseases, National Institutes of Health - December 14, 2004
In 1997, a clinical trial known as HIVNET 012 was begun in Uganda to address the developing world s urgent need for safe, effective and affordable regimens to prevent mother-to-infant transmission of HIV. The study was funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institut
The National Institute of Allergy and Infectious Diseases (NIAID) today announced that it is restructuring its HIV/AIDS clinical trials networks and soliciting investigators and institutions to lead the reorganized effort. This reorganization, designed in response to both the changing face of the AIDS epidemic and evo
National Institute of Allergy and Infectious Diseases, National Institutes of Health - November 30, 2004
Today, December 1, is World AIDS Day, a time to pause and remember all who have died from HIV/AIDS and reflect on the devastation this disease has caused around the world. It also is a day to recommit ourselves to doing all we can to develop accessible and affordable drugs to treat HIV disease and associated infections
Department of Health and Human Services - National Institute of Allergy and Infectious Diseases - National Institutes of Health
Media Contact: NIAID Office of Communications and Public Liaison (301) 402-1663, niaidnews@niaid.nih.gov
FOR IMMEDIATE RELEASE - Thursday, Nov. 18, 2004 HHS AWARDS $10.4 MILLION TO FIGHT AIDS ON THREE CONTINENTS HHS Secretary Tommy G. Thompson today announced four new grants totaling $10.4 million to provide support for HIV/AIDS research in Peru , Thailand ,
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Linda Joy, (301) 402-1663, ljoy@niaid.nih.gov
Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work. The cellular enzyme represents a potential new target for developing improved HIV drugs, say the researchers from the Natio
National Institute of Allergy and Infectious Diseases, National Institutes of Health - Friday, Oct. 15 2004
NIAID Press Office, (301) 402-1663
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is proud to commemorate the second annual National Latino AIDS Awareness Day (NLAAD), Oct. 15, 2004, along with hundreds of national, regional and local HIV/AIDS groups, state health departments and faith-based
HIV wreaks much of its damage by targeting the orchestra conductor of the immune system, a key class of T cells--CD4+ T cells--whose destructive relationship with HIV has been well-studied by AIDS researchers. More poorly understood has been the effect of HIV on another key class of immune cells, antibody-producing B c
National Institute of Allergy and Infectious Diseases - Wednesday, July 28, 2004
Linda Joy (301) 402-1663, ljoy@niaid.nih.gov
The preferred treatment for hepatitis C , peg-interferon and ribavirin, is safe for people who are also infected with HIV, according to a new study in the July 29 issue of The New England Journal of Medicine. Moreover, this treatment proved superior for the treatment of hepatitis C virus (HCV) in HIV-coinfected persons
At the XVth International AIDS Conference in Bangkok, Thailand , Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) and chief of the NIAID Laboratory of Immunoregulation (LIR), will present his laboratory s latest findings on how aberrant immune activation underlies HI
National Institute of Allergy and Infectious Diseases - Monday, April 26, 2004
Anne A. Oplinger (301) 402-1663 aoplinger@niaid.nih.gov
National Institutes of Health (NIH) scientists report that brief, widely-spaced courses of the experimental immune-boosting drug interleukin-2 ( IL-2 ) allow people with HIV to maintain near normal levels of a key immune system cell for long periods. The researchers, from NIH s National Institute of Allergy and Infecti
National Institute of Allergy and Infectious Diseases - Monday, April 19, 2004
Contact: Sarah Danberg, (703) 299-0878, sdanberg@idsociety.org
The HIV Medicine Association (HIVMA) and the Infectious Diseases Society of America (IDSA) are urging the Bush administration to adopt the World Health Organization s (WHO) quality standards for purchasing HIV/AIDS drugs instead of developing its own process that will take up precious time while lives are at stake. Un
National Institute of Allergy and Infectious Diseases - Monday, Jan. 26, 2004
Anne A. Oplinger (301) 402-1663 aoplinger@niaid.nih.gov
A new vaccine, made with several proteins from the bacterium that causes tuberculosis (TB), will soon enter the first phase of human safety testing. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has supported research on the candidate vaccine from its earl
This information is designed to support, not replace, the relationship that exists between you and your doctor.